TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36041466
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of self-disclosure and high communication competence
Study: 33306991
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg ID93 + 5 μg GLA‐SE on days 0 and 56
Study: 33306991
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg ID93 + 5 μg GLA‐SE on days 0, 28, and 56
Study: 35114131
Drug: High‐dose long‐acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐dose long‐acting octreotide
Study: 33831909
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to a single-tablet regimen of cobicistat, elvitregravir, emtricitabine along with tenofovir alafenamide
Study: 33831909
Drug: Two-drug regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug regimen based on dolutegravir and one reverse transcriptase inhibitor (RTI)
Study: 33378824
Drug: Quantitative fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantitative fecal immunochemical test (FIT) at a cutoff value of 20 μg Hb/g
Study: 33378824
Drug: Quantitative fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantitative fecal immunochemical test (FIT) at a decreased cutoff value of 5 μg Hb/g
Study: 36477547
Drug: No treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatments (control group)
Study: 32270926
Drug: Fenebrutinib 50
Normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenebrutinib 50 mg once daily
Study: 32270926
Drug: Fenebrutinib 200
Normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenebrutinib 200 mg twice daily (cohort 2)
Study: 34793986
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise therapy (SET) plus OMT
Study: 36329596
Drug: Esmolamine (0.1mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolamine (0.1mg/kg intravenous injection 10 min before induction, followed by 2 μg•kg‐1•min‐1 infusion)
Study: 36329596
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (control group)
Study: 34538227
Drug: five-flash intense
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: five-flash intense pulsed light therapy (IPL)
Study: 34549388
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous doses of S-oxiracetam (S-ORT) at 2.0 g, 4.0 g, and 8.0 g
Study: 34549388
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of 3.0 g S-ORT
Study: 34549388
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of 6.0 g racemic oxiracetam (R-ORT)
Study: 34549388
Drug: Daily intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intravenous injection of 4.0 g S-ORT for 7 days
Study: 34810345
Drug: Probiotic formulation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic formulation applied for 6 consecutive days
Study: 36228640
Drug: Daily contact
Normalized name: CONTACT LENS DAILY CLEANER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily contact testing (DCT) with seven lateral flow device (LFD) tests and two PCR tests, no isolation if negative on LFD.
Study: 35417909
Drug: Once-weekly somatrogon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly somatrogon (0.25, 0.48, and 0.66 mg/kg/week for 12 months)
Study: 35417909
Drug: Once-daily Genotropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily Genotropin (0.025 mg/kg/day for 12 months)
Study: 33588138
Drug: Dexamethasone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.4 ml/mg)
Study: 33588138
Drug: Long-acting betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting betamethasone (0.1 ml/mg)
Study: 36330832
Drug: Integrative adapt
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative adapt therapy (IAT)
Study: 33030089
Drug: Propranolol 60
Normalized name: propranolol 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 60 mg twice daily
Study: 32310040
Drug: Non-vitamin K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vitamin K antagonist oral anticoagulants
Study: 32310040
Drug: Dual-drug approach
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-drug approach with LMWH-VKA
Study: 36286945
Drug: Aterixen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aterixen (100 mg tablets)
Study: 34025069
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (wait-and-see approach)
Study: 33440985
Drug: Auricular acupressure
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupressure (AA) applied on four points: shemen, liver, spleen, and finger/toe, thrice daily for 3 weeks
Study: 33440985
Drug: Sham auricular
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham auricular acupressure applied on four remote points unrelated to neuropathic symptoms, thrice daily for 3 weeks
Study: 34107141
Drug: Spirulina supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina supplementation (1 g/day, two 500 mg capsules)
Study: 32579807
Drug: 320 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 μg budesonide, 18 μg glycopyrrolate, 9.6 μg formoterol (triple therapy)
Study: 32579807
Drug: 160 μg
Normalized name: immunoglobulin G, human 160 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 μg budesonide, 18 μg glycopyrrolate, 9.6 μg formoterol (triple therapy)
Study: 32579807
Drug: 18 μg
Normalized name: ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18 μg glycopyrrolate, 9.6 μg formoterol (dual therapy)
Study: 32579807
Drug: 320 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 μg budesonide, 9.6 μg formoterol (dual therapy)
Study: 32437937
Drug: Antibiotic prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescription
Study: 32945066
Drug: 30-g fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-g fecal microbiota transplantation (FMT)
Study: 32945066
Drug: 60-g fecal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-g fecal microbiota transplantation (FMT)
Study: 35986239
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment strategy based on preoperative risk score
Study: 35986239
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment strategy
Study: 35333352
Drug: Intensive breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive breast milk nutritional support program (IBNSP) with breastfeeding, administered for the first 48 hours after birth, including face-to-face training and practical support.
Study: 32149773
Drug: Methylprednisolone via
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone via intravenous injection at a dose of 1-2 mg/kg/day for 3 days
Study: 36003030
Drug: Instrumental reminiscence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrumental reminiscence therapy based on Roy's adaptation model
Study: 33092707
Drug: TMVr with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMVr with the MitraClip plus guideline-directed medical therapy (GDMT)
Study: 34481803
Drug: Nedosiran (1.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedosiran (1.5, 3.0, or 6.0 mg/kg)
Study: 34481803
Drug: Nedosiran (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedosiran (0.3, 1.5, 3.0, 6.0, then 12.0 mg/kg)
Study: 34362453
Drug: Intrathecal injection
Normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal injection of umbilical cord tissue mesenchymal stem cells (UCT‐MSC), single-dose (2 × 10^7) cells.
Study: 34768600
Drug: Dexamethasone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.8 mg) and Bupivacaine (5%) with articaine–epinephrine (40/0.005 mg/mL)
Study: 34768600
Drug: Articaine–epinephrine (40/0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine–epinephrine (40/0.005 mg/mL)
Study: 34481524
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g tranexamic acid (TXA) administered immediately after induction of general anesthesia
Study: 32305787
Drug: Very-low-dose spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-dose spinal analgesia (levobupivacaine 3.75 mg; sufentanil 2.5 μg)
Study: 32305787
Drug: Low-dose spinal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spinal analgesia (levobupivacaine 7.5 mg; sufentanil 2.5 μg)
Study: 32305787
Drug: Very-low-dose spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-dose spinal analgesia
Study: 32305787
Drug: Low-dose spinal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spinal analgesia
Study: 34481517
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg (with loading dose)
Study: 34481517
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg (without loading dose)
Study: 32446674
Drug: Established Status
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established Status Epilepticus Treatment Trial
Study: 35206521
Drug: Peer-delivered stop-smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-delivered stop-smoking programme (group support, combination nicotine replacement therapy (NRT), and tailored individual support)
Study: 32071149
Drug: Quercetin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin at 500, 1000 or 2000 mg/day for 1 week
Study: 32233245
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of PRP (2 ml) and extra-articular injection of PRP (2 ml), once a week for three times.
Study: 32233245
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of sodium hyaluronate (20 mg) and extra-articular injection of analgesic drug (2 ml for one point), once a week for three times.
Study: 33387398
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel containing onion extract and aloe vera (SGOA)
Study: 33387398
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheets (SGS)
Study: 35697424
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care followed by delayed treatment with TranS‐C (UC‐DT)
Study: 33877323
Drug: Liquid micellar
Normalized name: Douxo Micellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid micellar preparation (1000 mg)
Study: 33877323
Drug: Dried colloidal
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried colloidal suspension (300 mg)
Study: 33877323
Drug: Standard turmeric
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard turmeric extract (1500 mg)
Study: 33877323
Drug: Piperine-curcuminoid combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperine-curcuminoid combination (1515 mg)
Study: 33877323
Drug: Phytosome formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosome formulation (1000 mg)
Study: 34782419
Drug: IV thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV thrombolysis with alteplase at 0.9 mg/kg body weight
Study: 34106300
Drug: Sotagliflozin (SGLT2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotagliflozin (SGLT2 inhibitor)
Study: 34106300
Drug: Finerenon (mineralocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenon (mineralocorticoid receptor antagonist)
Study: 34106300
Drug: Kidney replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney replacement therapy initiation timing
Study: 33727902
Drug: Basic activities
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic activities of daily living
Study: 35140309
Drug: Oropharyngeal mother's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal mother's milk administration for 14 days
Study: 35140309
Drug: Oropharyngeal 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal 0.9% normal saline administration
Study: 32488680
Drug: CePROP =
Approvals — FDA: no, EMA: no, PMDA: no
Description: CePROP = 3.6 μg⋅ml−1 and CeREMI = 4 ng⋅ml−1
Study: 35751549
Drug: Dry cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry cupping therapy (DCT) for 8 minutes daily for 15 days (Group A)
Study: 35751549
Drug: Dry cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry cupping therapy (DCT) for 10 minutes daily for 15 days (Group B)
Study: 35751549
Drug: Dry cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry cupping therapy (DCT) for 12 minutes daily for 15 days (Group C)
Study: 33445205
Drug: GPB 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPB 1% cream
Study: 32125555
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy supplemented with 750 mg of S. boulardii CNCM I-745 daily for 2 weeks
Study: 34390556
Drug: 8 weekly
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weekly stress management sessions
Study: 33119680
Drug: Prescribed medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed medications during the previous year
Study: 33119680
Drug: Locally acting
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally acting antacids
Study: 33119680
Drug: Loop diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics (e.g., furosemide)
Study: 33119680
Drug: Major cardiovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Major cardiovascular drug classes
Study: 32639688
Drug: Cluster needling
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster needling of scalp acupuncture on top of drug treatment
Study: 35466438
Drug: Acalabrutinib suspension
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acalabrutinib suspension (Acala-NG) administered via NG tube
Study: 35466438
Drug: Acalabrutinib suspension
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acalabrutinib suspension (Acala-NG) with PPI (rabeprazole)
Study: 35466438
Drug: Oral acalabrutinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acalabrutinib capsule administered with water
Study: 35178208
Drug: Melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6 mg BD for 3 days)
Study: 33465285
Drug: ELX-02 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELX-02 at 5.0 mg/kg
Study: 32889781
Drug: High hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High hormone (HH) phase
Study: 34530059
Drug: ART (Alternative
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART (Alternative Restorative Treatment)
Study: 34248187
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (10 ml of normal saline) prior to interscalene block
Study: 34248187
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (no saline injection)
Study: 32289479
Drug: 8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/day valacyclovir
Study: 33257495
Drug: Person-Centred Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person-Centred Therapy (PCT)
Study: 33722999
Drug: Bromhexine 8
Normalized name: bromhexine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine 8 mg four times a day in addition to standard therapy
Study: 33722999
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (lopinavir/ritonavir and interferon beta-1a)
Study: 35196591
Drug: 0.1% nepafenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% nepafenac eye drops thrice daily for 2 weeks
Study: 35196591
Drug: 0.09% bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.09% bromfenac eye drops twice daily for 2 weeks
Study: 35288148
Drug: 1-L PEG
Normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-L PEG with low-dose ASC (50% lower ASC concentration)
Study: 35288148
Drug: 1-L PEG
Normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-L PEG with low-dose ASC (25% lower ASC concentration)
Study: 35288148
Drug: 1-L PEG
Normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-L PEG with low-dose ASC
Study: 35144649
Drug: Fish Oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish Oil (FO) at a dose of 3 g/day containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
Study: 35144649
Drug: Perilla Oil
Normalized name: Perilla frutescens leaf oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perilla Oil (PO) at a dose of 3 g/day containing α-linolenic acid (ALA)
Study: 35144649
Drug: Linseed and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linseed and Fish Oil (LFO) at a dose of 3 g/day containing EPA, DHA, and ALA
Study: 32402523
Drug: Treatment Initiation
Normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Initiation Program (adherence intervention)
Study: 32238091
Drug: MF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF therapy combined with chemotherapy
Study: 32238091
Drug: Sham MF
Normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham MF therapy combined with chemotherapy
Study: 33497537
Drug: Valsartan/cilnidipine (80/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/cilnidipine (80/10 mg)
Study: 33497537
Drug: Valsartan/hydrochlorothiazide (80/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/hydrochlorothiazide (80/12.5 mg)
Study: 32235144
Drug: Multimodal analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesic regimen including acetaminophen 1,000 mg, gabapentin 600 mg, ketamine 5 µg/kg/min, and lidocaine 1.5 mg/kg/h
Study: 32235144
Drug: Multimodal analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesic regimen
Study: 35104665
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg, monthly intravenous for 6 months)
Study: 32830326
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy intervention (12-week duration)
Study: 32830326
Drug: Therapeutic alliance
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic alliance and number of therapeutic techniques (treatment-specific predictors)
Study: 35371277
Drug: Intensive hand
Normalized name: ALCOHOL 350 mL in 500 mL TOPICAL GEL [CLEAN UP Intensive Hand Sanitizer Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive hand training on the basis of routine rehabilitation treatment (including inducing five finger extension, forcibly pulling fingers and wrist joints, suddenly opening fist after clenching fist)
Study: 35371277
Drug: Routine rehabilitation
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine rehabilitation treatment (including routine joint activity training, bed training, exercise therapy, and ADL ability training)
Study: 32252674
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVA) injection followed by panretinal photocoagulation (PRP)
Study: 34190207
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy followed by autologous stem cell transplantation (HD-ASCT)
Study: 34209131
Drug: Pharmacogenetic dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic dosing algorithm
Study: 34209131
Drug: Standard-of-care dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care dose adjustment
Study: 32744512
Drug: HBsAg <20,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg <20,000 IU/ml
Study: 33774968
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of diltiazem gel
Study: 33774968
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no diltiazem gel)
Study: 33657871
Drug: Auricular intradermal
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular intradermal acupuncture (AIA)
Study: 32106792
Drug: Alendronate/Vitamin D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate/Vitamin D3 70 mg/5600 IU for 24 weeks (concomitant treatment arm, CTA)
Study: 32106792
Drug: Alendronate/Vitamin D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate/Vitamin D3 70 mg/5600 IU starting 24 weeks after study entry (delayed treatment arm, DTA)
Study: 32106792
Drug: No bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bone anti-resorptive therapy (standard of care, SOC)
Study: 32535917
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon (Si) at 2 mmol L‐1
Study: 35120306
Drug: Anti-EGFR agent
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-EGFR agent
Study: 32183793
Drug: Dialectical Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behaviour Therapy (DBT) - weekly individual cognitive behavioural therapy sessions and a 2.5 h skills training group session twice per week for 6 months